SYNACT Share Price Performance
SEK 0
-18.72 (-100.00%)
Price SEK 0
Share Pricen/a
Analysis Article • May 28
SynAct Pharma AB Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
SYNACT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
SynAct Pharma AB Key Details
About SYNACT
- Founded
- 2012
- Employees
- 8
- CEO
- WebsiteView website
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
